ARTARA THERAPEUTICS INC TARA 深 滬
已收盤 12-24 16:00:00 美东时间
5.49
+0.120
+2.23%
華盛通- 最 高5.50
- 今 開5.37
- 成交量 23.51万股
- 最 低 5.36
- 昨 收 5.37
- 總市值 2.12亿
- 52周最高 7.82
- 市盈率 靜 --
- 換手率 0.61%
- 52周最低 2.77
- 委 比 -22.52%
- 總股本 3858.73万
- 歷史最高 800.00
- 量 比 0.36
- 振 幅 2.61%
- 歷史最低 1.04
- 每 手 1
- 風險率 1.09%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Protara Therapeutics Completes $75 Million Stock Offering
An update from Protara Therapeutics ( ($TARA) ) is now available. On December 4...
12-09 05:53
Protara Therapeutics slumps 12%, raises $75M equity at $5.75 per share
Protara Therapeutics (TARA) priced its underwritten public offering of ~13.04M shares at a price to the public of $5.75 per share. The underwriters have a 30-day option to purchase up to an additional...
12-05 14:01
Protara Announces Proposed Public Offering
Protara Therapeutics announced the commencement of a public offering of up to $75 million in common stock or pre-funded warrants, with potential additional shares based on underwriter demand. Proceeds will fund clinical development of TARA-002 and other programs, as well as general corporate purposes. J.P. Morgan, TD Cowen, and Piper Sandler are joint book-running managers. The offering is subject to market conditions and SEC registration.
12-04 21:15
Protara Therapeutics To Review Data From Interim Analysis On Phase 2 ADVANCED-2 Study Of TARA-002 In BCG-Naive Participants With Non-Muscle Invasive Bladder Cancer On Dec. 3
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it will host a conference call and live webcast
12-02 05:18
美股大行评级 | 高盛上调百度、美敦力、晶科能源等多只个股目标价；家得宝遭9家机构下调目标价；
今日重点评级关注：富国银行：维持Annexon"超配"评级，目标价从14美元升至27美元；瑞穗：上调Relmada Therapeutics评级至"跑赢大市"，目标价从1美元升至10美元
11-20 10:28
What's Going On With Protara Therapeutics Stock Wednesday?
TARA-002, a cell-based therapy by Protara Therapeutics, shows promising results in treating lymphatic malformations in pediatric patients.
11-20 03:18
美股牛股 | 嘉楠科技飙升20%，Q3挖矿收入激增241%；Diginex涨超19%，公司与EVIDENT达成战略合作
嘉楠科技飙升20%，Q3营收破1.5亿美元，挖矿收入激增241%；Diginex涨超19%，公司与EVIDENT达成战略合作>>
11-19 16:54
Protara Therapeutics To Present Interim Data From Group A Of Phase 2 ADVANCED-2 Study Of TARA-002 In BCG-Naive Participants With Non-Muscle Invasive Bladder Cancer
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that interim data from Cohort A of the ongoing Phase
11-17 21:07
Protara Therapeutics Q3 EPS $(0.31) Beats $(0.38) Estimate
Protara Therapeutics (NASDAQ:TARA) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.38) by 19.27 percent. This is a 38 percent increase over losses of $(0.50) per share from
11-10 21:14
Protara Therapeutics Named a 2026 Best Places to Work Winner by BioSpace
Protara Therapeutics has been named a BioSpace 2026 Best Place to Work in the small employer category. CEO Jesse Shefferman praised the company's culture and team, emphasizing their commitment to fostering a vibrant environment that attracts top talent. Protara, based in NYC, offers competitive benefits, professional growth opportunities, and values inclusivity and work-life balance. The company focuses on developing transformative therapies for ...
11-04 21:05
